InflaRx (IFRX) Current Taxes (2016 - 2026)

InflaRx's (IFRX) quarterly Current Taxes came in at $15.4 million in Q2 2026, up 128.38% quarter-over-quarter from $6.8 million in Q4 2025.

Analysis

InflaRx (IFRX) Current Taxes (2016 - 2026) Analysis & Trends

InflaRx has disclosed Current Taxes across 6 years of filings, most recently posting $15.4 million for Q2 2026.

In Q2 2026, Current Taxes changed N/A year-over-year to $15.4 million; the TTM figure through Jun 2026 stood at $15.4 million (changed N/A YoY), while the FY2025 annual figure was $6.6 million, changed N/A from the prior year.
Current Taxes came in at $15.4 million for Q2 2026 at InflaRx, up from $6.8 million in the prior quarter.
In the past five years, Current Taxes ranged from a high of $15.4 million in Q2 2026 to a low of $6.8 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Taxes (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	-
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	-
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	49.00 Mn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	86.90 Mn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	74.18 Mn
10	InflaRx	139.29 Mn	-44.96 Mn	2.74 Mn	15.42 Mn

Historic Data

Download Data